98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jchf.2025.04.004 | DOI Listing |
Imaging Neurosci (Camb)
July 2025
Department of Psychology (Experimental Clinical Psychology), University of Würzburg, Würzburg, Germany.
Adapting behavior to environmental demands is a fundamental aspect of survival. In the face of unfamiliar potential dangers, organisms display a wide range of defensive mechanisms, such as using contextual information to prepare for upcoming threats and extrapolating from previous experiences with similar encounters (threat generalization). Importantly, these different types of threat-related information place distinct demands on the attentional system: potential, context-related threat induces a state of hypervigilance, whereas imminent, acute threat requires selective attention.
View Article and Find Full Text PDFJACC Heart Fail
April 2025
Mass General Brigham Heart and Vascular Institute and Harvard Medical School, Boston, Massachusetts, USA. Electronic address:
Wilderness Environ Med
September 2025
Department of Emergency Medicine, University of California San Francisco Fresno, Fresno, CA, USA.
Climate change contributes to warm, dry conditions, which leads to longer and more active fire seasons. Wildland firefighters work long hours in smoky conditions without regulations requiring respiratory protection. Wildfire smoke has many toxic components, including high levels of fine particulate matter (PM).
View Article and Find Full Text PDFActa Trop
December 2024
Department of Microbiology and Environmental Toxicology, University of California at Santa Cruz, Santa Cruz, CA 95064, USA. Electronic address:
Dengue fever is a mosquito-transmitted disease of great public health importance. Dengue lacks adequate vaccine protection and insecticide-based methods of mosquito control are proving increasingly ineffective. Here we review the emerging use of mosquitoes transinfected with the obligate intracellular bacterium Wolbachia pipientis for vector control.
View Article and Find Full Text PDFPediatr Pulmonol
December 2024
National Heart and Lung Institute, Imperial College London, London, UK.
Novel biologics (targeted antibody therapies) have revolutionized the management of severe childhood asthma. However, it is important that the right biologic is selected for the right patient, and understanding the evidence base for each biologic is crucial. Currently, four biologics (all monoclonal antibodies) are licensed in the UK for the treatment of children with severe asthma - omalizumab (Xolair), mepolizumab (Nucala), and dupilumab (Dupixent) in children aged 6 years and over; and tezepelumab (Tezspire), only in children aged 12 years and over.
View Article and Find Full Text PDF